Drug Trial Radar · NCT00264901
Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Jan 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,652
Actual
Start
Oct 2005
Primary completion
Nov 2006
Study completion Nov 2006
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Dec 13, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in the United States of America (USA). This trial aims for a comparison of the safety and efficacy in subjects with type 2 diabetes using either self titration or physician guided titration according to the local standard of care.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
insulin detemirDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of the change from baseline to end of treatmentTime frame: after 26 weeks in the value of laboratory-measured HbA1c between the self adjustment versus the standard of care group
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Plainsboro, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.